SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-24-042645
Filing Date
2024-04-08
Accepted
2024-04-08 16:40:10
Documents
21
Period of Report
2024-05-29

Document Format Files

Seq Description Document Type Size
1 PRE 14A kpti-20240408.htm   iXBRL PRE 14A 2347586
2 GRAPHIC img95390175_0.jpg GRAPHIC 33329
3 GRAPHIC img95390175_1.jpg GRAPHIC 8774
4 GRAPHIC img95390175_2.jpg GRAPHIC 33329
5 GRAPHIC img95390175_3.jpg GRAPHIC 114247
6 GRAPHIC img95390175_4.jpg GRAPHIC 247114
7 GRAPHIC img95390175_5.jpg GRAPHIC 217260
8 GRAPHIC img95390175_6.jpg GRAPHIC 232988
9 GRAPHIC img95390175_7.jpg GRAPHIC 234691
10 GRAPHIC img95390175_8.jpg GRAPHIC 209096
  Complete submission text file 0000950170-24-042645.txt   6428586

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20240408.xsd EX-101.SCH 29773
24 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20240408_htm.xml XML 165637
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36167 | Film No.: 24830098
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)